AN2 Therapeutics Q1 net loss $16.6M; Phase 2 TR-MAC data expected August 2024

AN2 Therapeutics, Inc.

2024-Q1 EPS reported -$0.56

Net loss of $16.6M for Q1 2024 vs $15.3M in Q1 2023; cash $118.1M.
R&D spend $14.7M, up from $12.0M YoY; G&A $3.6M, down from $4.1M.
Phase 3 enrollment paused Feb 2024 due to blinded aggregate efficacy signal; no safety issues.
97 patients remain in Phase 3; topline Phase 2 data from EBO-301 due August 2024.
Epetraborole targets treatment-refractory MAC lung disease with high unmet need.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AN2 Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $16.6 million.

Period: the quarter ended March 31, 2024
Net income: Net loss for the first quarter of 2024 was $16.6 million
Result: reported results

Exact text from the filing

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

AN2 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-059527

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.